Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:AGRX NASDAQ:COEP NASDAQ:GRCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.24-2.4%$1.29$1.05▼$10.16$38.87M1.65270,335 shs122,862 shsAGRXAgile Therapeutics$1.51$1.49$0.20▼$2.63$10.35M1.58352,864 shs120,938 shsCOEPCoeptis Therapeutics$11.16+5.3%$9.39$2.31▼$13.70$39.17M-0.5957,220 shs47,809 shsGRCEGrace Therapeutics$3.22+9.2%$3.05$1.75▼$4.97$44.53M0.7269,926 shs171,951 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics0.00%-1.59%-6.06%+3.33%-83.88%AGRXAgile Therapeutics0.00%0.00%0.00%0.00%+3.78%COEPCoeptis Therapeutics0.00%+4.10%+18.58%+12.73%+176.24%GRCEGrace Therapeutics0.00%+12.20%-6.40%+18.38%+321,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRVAcrivon Therapeutics2.5656 of 5 stars3.55.00.00.00.01.70.6AGRXAgile TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$17.711,328.57% UpsideAGRXAgile Therapeutics 0.00N/AN/AN/ACOEPCoeptis Therapeutics 0.00N/AN/AN/AGRCEGrace Therapeutics 3.00Buy$12.00272.67% UpsideCurrent Analyst Ratings BreakdownLatest AGRX, ACRV, COEP, and GRCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ACRVAcrivon TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/15/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/AAGRXAgile Therapeutics$19.98M0.52N/AN/A($5.51) per share-0.27COEPCoeptis TherapeuticsN/AN/AN/AN/A$1.61 per shareN/AGRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.22N/AN/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)AGRXAgile Therapeutics-$14.47M-$3.65N/A∞N/A-36.24%N/A-147.37%N/ACOEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-282.39%-127.23%N/AGRCEGrace Therapeutics-$9.57M-$0.89N/AN/AN/AN/A-19.45%-16.99%N/ALatest AGRX, ACRV, COEP, and GRCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ACRVAcrivon Therapeutics-$0.57N/AN/AN/AN/AN/A6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23-$0.21+$0.02$0.01N/AN/A5/14/2025Q1 2025COEPCoeptis TherapeuticsN/A-$1.11N/A-$1.11N/AN/A5/13/2025Q1 2025ACRVAcrivon Therapeutics-$0.57-$0.51+$0.06-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/AAGRXAgile TherapeuticsN/AN/AN/AN/AN/ACOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A11.1711.17AGRXAgile TherapeuticsN/A0.560.38COEPCoeptis Therapeutics0.020.820.82GRCEGrace TherapeuticsN/A11.7711.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%AGRXAgile Therapeutics10.92%COEPCoeptis Therapeutics13.88%GRCEGrace Therapeutics6.08%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%AGRXAgile Therapeutics0.50%COEPCoeptis Therapeutics24.25%GRCEGrace Therapeutics11.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.35 million28.69 millionNot OptionableAGRXAgile Therapeutics306.86 million6.82 millionNot OptionableCOEPCoeptis Therapeutics23.51 million2.66 millionNot OptionableGRCEGrace TherapeuticsN/A13.83 million12.29 millionN/AAGRX, ACRV, COEP, and GRCE HeadlinesRecent News About These CompaniesGRCE: NDA SubmittedJune 26, 2025 | msn.comGrace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104June 25, 2025 | globenewswire.comGrace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update - MorningstarJune 24, 2025 | morningstar.comMGRACE THERAPEUTICS Earnings Preview: Recent $GRCE Insider Trading, Hedge Fund Activity, and More - NasdaqJune 24, 2025 | nasdaq.comGrace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near FutureJune 24, 2025 | finance.yahoo.comGrace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business UpdateJune 23, 2025 | globenewswire.comGrace Therapeutics to Participate in the 2025 BIO International ConferenceJune 13, 2025 | globenewswire.comGRCE: Progress ReportJune 5, 2025 | msn.comGRCE Grace Therapeutics, Inc.June 1, 2025 | seekingalpha.comThis Grace Therapeutics Insider Increased Their Holding By 12% Last YearMay 25, 2025 | finance.yahoo.comBiotech Stock Ends Week On High Note Following Bullish Coverage InitiationMay 2, 2025 | msn.comGrace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104April 9, 2025 | globenewswire.comGrace Therapeutics files to sell 8.84M shares of common stock for holdersMarch 10, 2025 | markets.businessinsider.comGrace Therapeutics Files Form S-3 for Flexible Securities OfferingMarch 10, 2025 | tipranks.comNew Biotech Stocks at Investorideas.comFebruary 28, 2025 | investorideas.comIGrace Therapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comGRCE: STRIVE-ON Results ReportedFebruary 21, 2025 | finance.yahoo.comGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateFebruary 13, 2025 | markets.businessinsider.comGrace Therapeutics reports Q3 EPS (36c), consensus (46c)February 13, 2025 | markets.businessinsider.comGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateFebruary 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGRX, ACRV, COEP, and GRCE Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.24 -0.03 (-2.36%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.25 +0.01 (+1.21%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Agile Therapeutics NASDAQ:AGRXAgile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.Coeptis Therapeutics NASDAQ:COEP$11.16 +0.56 (+5.28%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$11.20 +0.04 (+0.36%) As of 08/8/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.Grace Therapeutics NASDAQ:GRCE$3.22 +0.27 (+9.15%) As of 08/8/2025 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.